Russian PM Vladimir Putin has spoken. Foreign drug manufacturers who want to operate in Russia will need to manufacture there and to transfer technology to the local economy or face restrictions to the market. Putin's Russia plans to raise the domestic pharmas share of the Russian drug market to more than 30%.
Big Pharma has heard the message and is responding. Teva will expand its Russian manufacturing operations in the country. It has pledged to invest $100 M to bolster its goal of tripling its sales in Russia by 2015.
GSK will also pour cash into the emerging Russian market. It struck a deal earlier this year to invest in Russia's Binnopharm to produce cervical cancer, rotavirus and pneumococcal vaccines for the domestic market.
The drug makers Novo Nordisk, Sanofi-Aventis, AstraZeneca, Novartis, Pfizer and Nycomed also plan to place manufacturing in the Russian market through building or partnerships. See in-PharmaTechnologist
Posted by Bruce Lehr Jan 26th 2011.